ab-836
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 25, 2021 (NCT04775797)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Hepatitis B virusINHIBITOR
Hepatitis B virus inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
C[C@H](c1c[nH]c(=O)c2cc(F)c(F)cc12)N(C)C(=O)Nc1ccc(F)c(C#N)c1- Mol. weight
- 400.36 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314907 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04775797 | Phase 1 | Mar 25, 2021 | Arbutus Biopharma Corporation |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Arbutus Biopharma Corporation | For profit | 1 | 1 | 1 | 2021 |
1 organizations
Page 1 / 1